Advanced Cell Diagnostics and Kindstar Global Announce Partnership to Launch Cancer Diagnostic Tests in China
HAYWARD, CA & WUHAN, CHINA, Oct. 23, 2013—Advanced Cell Diagnostics, Inc. (ACD) and Kindstar Global (Kindstar) today announced that Kindstar will begin validating and implementing ACD’s RNAscope® technology-based molecular diagnostic assays in its clinical laboratories. The initial suite of tests to be launched include RNAscope HPV, a high-risk HPV test to determine HPV status in cervical pre-cancer and head & neck cancer, and CTCscope, a blood-based test to detect and characterize circulating tumor cells in blood. This partnership will enable Kindstar to leverage ACD’s RNA biomarker analysis platform to offer a new generation of cancer diagnostic tests to its network of more than 3,300 hospitals across China.
"Kindstar's adoption of ACD’s RNAscope technology for advanced molecular testing in oncology attests to the broad clinical utility of RNAscope." said Dr. Yuling Luo, Founder, President and CEO of Advanced Cell Diagnostics. "RNAscope technology enables a dramatic improvement in diagnostic accuracy and confidence, especially when cellular and molecular context is required and when more sensitive technology is needed to give a conclusive result.”
"Kindstar is excited to offer services in China based on the most advanced RNA in situ hybridization platform in the industry. The new RNAscope-based tests will significantly broaden Kindstar’s oncology test menu offerings. The RNAscope platform will also allow Kindstar to more rapidly translate today’s advances in cancer research into clinical practice for our physicians and patients," said Dr. Shiang Huang, Founder and CEO of Kindstar. "
About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue-based research tools for all areas of biomedical research, and diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the most sensitive method available for RNA in situ hybridization, and the first quantitative and fully automated platform enabling multiplex fluorescent and chromogenic RNA biomarker analysis. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com.
About Kindstar Global
Kindstar Global, with laboratory facilities in Beijing, Shanghai and Wuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province of China. Kindstar is the first and largest esoteric diagnostic testing business in China, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 tertiary hospitals (classification for largest leading hospitals). Kindstar is becoming the partner of choice to physicians in China for advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics.